Maximum quantity allowed is 999
Please select the quantity
CAS RN: 700874-72-2 | Product Number: G0639
Galunisertib
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- LY-2157299
- 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 100MG |
₩501,400
|
11 | 0 | Contact Us |
* Please contact our distributor of SEJIN CI Co., Ltd.
if you would like to purchase TCI products. The above prices do not include freight cost, customs charge and other charges to the destination. SEJIN CI Co., Ltd. (Phone: 02-2655-2480 / email:
sales@sejinci.co.kr)
* The storage conditions are subject to change without notice.
* The storage conditions are subject to change without notice.
| Product Number | G0639 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__2H__1__9N__5O = 369.43 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive,Heat Sensitive |
| Packaging and Container | 100MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 700874-72-2 |
| Reaxys Registry Number | 14275134 |
| MDL Number | MFCD12923319 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Melting point | 246.0 to 250.0 °C |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 248 °C |
GHS
Related Laws:
Transport Information:
| H.S.code* | 2933.49-000 |
Application
Galunisertib: An Oral and Selective TGF-β Receptor Type I (TGF-βR type I) Kinase Inhibitor
Transforming growth factor-beta (TGF-β) signaling regulates a wide range of biological processes. It has been reported that TGF-β plays an important role in tumorigenesis and migration of cancer cells.1) Galunisertib (LY2157299 monohydrate) is an oral and selective TGF-β receptor type I (TGF-βR type I) kinase inhibitor, and it has been used to study the role of TGF-β signaling in chemotherapy-induced expansion of cancer stem-like cells.2,3) (The product is for research use only.)
References
- 1) TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- 2) Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
- 3) Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.